SGX942 Approval Status
- FDA approved: No
- Brand name: SGX942
- Company: Soligenix, Inc.
- Treatment for: Mucositis
SGX942 is an innate defense regulator (IDR) in development for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients.
Development Status and FDA Approval Process for SGX942
|Jun 3, 2013||FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.